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Epidarmal growth factor (EGF) induces transformed phcnotypcs in EGF receptor-overexpressing NlH3T3 (ERl2) cells. Tyrosine kinazc inhibitors 
such as crbstatin and its stable analoyue methyl 2,%dihydroxycinnamate inhibited the EGF-induced phcnotypic han~cs in these cells, while 
5’-O-mcthylcrbstatin, an inactive analoguc, did not. Methyl 2,5-dihydroxycinnomatc inhibited intracellular tyrosine kinasc activity in EGF-treated 
ERl2 cells. Methyl 2,5-dihydroxycinnamatc also delayed the EGF-induced DNA synthesis from the quiescent phase ER12 cells without showing 
irrevcrsiblc ytotoxicity. It inhibited the DNA synthesis most efficiently nt the arly G, phase. Thus, tyrosine kinnse inhibitors may modify malignant 
phenotypes in EGF receptor-overexpressing neoplasms. 
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1. 1NTRODUCTION 
Overexpression of epidermal growth factor (EGF) 
receptors has been reported in various tumour cell lines, 
and it has been suggested that amplified normal EGF 
receptors could contribu::: to tumc,rigenesis [l-3]. The 
ER12 cell line is a transfectant of human EGF receptor 
cDNA to the NIH3T3 cell line and shows various types 
of phenotypic transformation in response to EGF [4]. 
Including the ER 12 cell line, several aboratories estab- 
lished EGF receptor-transfected cell lines and reported 
ligand-dependent transformation of these cells [5,6]. 
For instance, in the presence of EGF, the cells become 
less dependent on serum, lose contact inhibition, and 
acquire growth advantage and anchorage-independent 
growth ability. 
The activated EGF receptor has iyrosine kinase ac- 
tivity in its cytoplasmic portion, which is essential for 
the EGF-EGF receptor-mediated proliferation signal. 
Many oncogene products such as Erb B, Erb B2, Fms, 
Src, and Abl also have Lyrosine kinase activity. Al- 
though the main target of the tyrosine kinase is not 
known, the kinase of the EGF receptor is considered to 
act on phospholipase C-y [7], phosphatidylinositol 3’- 
kinase [S], and GAP [!I]. 
Erbstatin was isolated from Srrcprotnyces as an inhib- 
itor of EGF receptor tyrosine kinase, and methyl 2,5- 
dihydroxycinnamate (2,5-MeC) is a stable analoguc of 
it [lo]. Both were shown to delay the onset of EGF- 
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induced DNA synthesis in normal rat kidney (NRK) 
~~11s [II]. They also inhibited Src-induced disruption of 
actin stress fiber organization and enhanced fibronectin 
expression in RSVU-NRK cells [12]. In the present 
study, we examined the effect of 2,5-MeC on EGF- 
induced morphological transformation, cytoske!ctal or- 
ganization, fibronectin expression, and DNA synthesis 
in the ER12 cell line. 
2. MATERIALS AND METHODS 
The ER12 cell line was prepared as described previously [4]. Calf 
serum (CS) was purchased from Gibco. Epidcrmal growth factor was 
purchased from Biomedical Technologies. Erbstatin was isolated from 
Srrrprornyce~ asdcscribcd I1 01. Methyl 2,5-dihydroxycinnamntc and 
5’-O-mcthylerbstatin were synthcsizcd in our laborAtory. Anti-mouse 
Rbronectin polyclonal antibody was purchased from UCB Bio- 
producls; and rhodamine-conjugatcd phalloidin. from Molecular 
Probes Inc. 1z51-labcllrd protein A (3.7 MBq/ml) was purchased from 
Amursham. 
2.2. Cell nrfturr 
ER12 cells were grown in Dt&ccco’s modified Eagle’s medium 
(DMEM) containing 5% CS at 37% in a 5% Cod9596 air atmosphere. 
2.3. Cdhiiar nrorpt~olo~y 
ER12 cells (5 x IO’) plated in 24-m plastic dishes were grown for 
IG h Wore use. Then 10 ndml of EGF and test chemicals were added 
and the cells were examined byphase-contrast microscopy. Appropri- 
ate controls were run to test the ffixts of the solvents. All the monpho- 
logical and Ruorescence staining experimcnu were repeated twice or 
more. 
2.4. Ftuorrsccnce srrrining 
ERl2 cells grom~ on cover glasses were treated with 10 @ml of 
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Fig. 1. Inhibition of EGF-induced diir@on & setin .Glxr w\&z&is h,~ Z$-_Pr .i~ EJKJ p&s YLbfi& MV .iw~titi .a.bw ,$Q .w+.b .w 
ndml of EGF (B), or with EGF and 1.6 iug/rnl of 2,5-M& (C) for 16 11, and then stained with rhodamin-phalloidin for visualization of actin. 
EGF and test chcmicats Car 16 h and !&.ed with 3,5% ,oar;ll‘onn;llds- 
lude in Ca2’,Mg’+-frcc phosphate-bulked saline (PBS) for 29 min nt 
mom temperature. After abriet rinse ti Cal‘,Mgz’-frsc PBS, the fixed 
ceS wcrc p~rm&Zzeo dti D,SY& TrjJo_n X -1 BD jn C+,YQ? -j>z 
PBS. The cover glasses wcrc washed with Caz’,Mgz’-free PBS and 
incubated for 20 min at 37’C with rhodamine-conjugated phalloidin 
to demxt polymerized actin or with the specific antibody to detect 
fibronectin. They were washed with Ca’+,Mg?‘-free PBS and exam- 
incti by fluorescence microscopy. 
ER 12 cells (1.5 x IO’) plated in 35-mm plastic dishes were grown for 
16 h before USC. The cells were treated with IO ng/ml of EGF and test 
chemicals for 16 1~. After u brief rinse with Ca’+,Mg’+-free PBS, the 
cells were extracted with 2OOyl of rndioimmuno precipitation (RIPA) 
buffer for 30 min at 4°C. The cell lysatcs were centrifuged ut 15.000 
x g for 5 min. Then LOO ,ul of the supernatant was added to 100 ~1 of 
sample buffer (42 mM Tris-I-K!. !O%,- glycerol, 2.3% SDS, 5% 2- 
mercaptoethanol, 0.002% bromophcnol blue, pH 63) and electro- 
phorescxl on a 7% polyacrylamide gel. Proteins were transferred to a 
nitrocellulosc filter and incubated with anti-libroncctin antibody for 
30 min at 37°C. A.ftcr a brief rinse, the filter was reacted with rzJ1- 
protein A for 16 h at 4°C. Fibronectin bands were visualized by 
autoradiography. 
When the immunoblotting analysis was performed with anti- 
phosphotyrosinc antibody, addition of 2,5-McC or erbstatin gave 
unwanted backgrounds. Tharcrore, the cell lysate wts precipitated 
with the anti-EGF receptor antibody tirst, and then the in vitro tyro- 
sine kinnse of the precipitate was assayed. Intact ER I? cells (about 4 
x 105) were treated with various concentrations of2,5-MeC in serum- 
free DMEM for I5 min. and EGF (100 ngIm1) was added for furthe) 
5 min. The cells were collected and solubilized with 1% Triton X-100 
in 20 mM HEPES (pH 7.4) containing 10% glycerol, 0.1 mg/ml oi 
Icupcptin, 1 mM PMSF, and 100 pM Na>VO, at 4OC for 30 min. An 
nliqruot of solubilized material was reacted with anti-EGF receptor 
antibody for 16 h at 9C. and tl~ccomplcxcs formed were immunoprc- 
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Fig. 2. Inhibition of EGF-induced reduction in fibroncctin expression 
by tyrosine kinasc inhibitors in ERl2 cells. The cells were incubated 
without additive (Lane 1 j, or with 10 ndmi of EGF (2), ECF and 3.2 
(3) or 1 .G (4) pgrnl of erbstatin, or EGF and 3.2 (5) or I6 (G) pg/ml 
of 2.5-M&, for I6 11, and then processed for immunoblotting as 
described in Section 2. 
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3. RESULTS 
Methyl Z,S-dihydroxycinnamate inhibited the growth 
of ER12 cells with an KS, of 0.5 lug/ml. In the presence 
of EGF, it inhibited the EGF-stimulated growth with 
almost the same lCsO value. Erbstatin inhibited the cell 
growth with an lCsO value of 1.65 pg/ml both in the 
absence and in the presence of EGF. 
Time 1 hrsl 
ER12 cells show normal fibroblastic morphology in 
eke absence of EGF, but within JS JI of she addjkm of 
IO r~gkid EGF clle cells assume a thin ad slightly crks- 
crossing transformed morphology (41. Methyl 2,5-&y- 
droxycinnamate and erbstatin did not clearly inhibit the 
EGF-induced morphologkd change because the effect 
of EGF was not prominent. However, as shown in Fig. 
IA,B, actin stress fiber organization was clearly ob- 
served in non-treated ER12 cells but not in EGF-treated 
cells. When EGF was added in the presence of OS-i.6 
&ml of 2,5-MeC, stress fiber organization was re- 
tained at the corurol level (Fig. IC). The effect of 2,5- 
Time Ihrs) 
Fig. 4. Inhibition or EGP-induced DNA synthesis in quiescccnt EF.12 cciis by 2,.5-i&2. (A) @icXi-fit Er?:2 SC15 WCiC XtEXIZ! <,L). 0: ~¶Z2l.E! 
with 40 ng/ml of EGF alone (o), or EGF and I (a), 2 (v), 4 (o), or 8 (m) ydml of 2.SMcC. Labellctl thymidinc was added LO the cells for 1 h 
at the indicated time. (13) The cells were untreated (A), or trcatcd with EGF alone (0). or EGF and 8 jfp/ml or 2.5.McC al O-rl h (A). 4-8 h (V), 
8-12 h (c). or O-32 h (0) from the time of EGF addition. 
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Fig. 5. In situ inhibition of EGF rcczptor-associated tyrosinc kinase 
by 2,5-M&. The cells were untreated (Lane I), or treated with 100 
n@nl of EGF (2), or EGF and 3 (3) or 6 (4) ,@ml of 2,5-M& for 15 
min. Precipitation of the cell lysate and the in vitro tyrosine kinase 
assay were carried out as described in Section 2. 
MeC or erbstatin was reversible, since after the removal 
of the chemicals the cellular cytoskeletal change was 
induced by addition of EGF. An inactive analogue S- 
O-methylerbstatin did not inhibit the cytoskeletal 
change induced by EGF. 
Fibronectin gene expression is usually less in trans- 
formed cells than in normal cells. As shown in Fig. 2, 
the amount of Abronectin decreased 16 h after addition 
of EGF, but 2,5-MeC or erbstatin inhibited this de- 
crease, These inhibitory effects were confirmed by im- 
munofluorescence staining (Fig. 3). 
Methyl 2,5-dihydroxycinnamate d layed the onset of 
EGF-induced DNA synthesis in quiescent ER 12 cells at 
1 .O-8.0 p&ml, as shown in Fig. 4A, and it inhibited the 
DNA synthesis most efficiently when added ai: the early 
G, phase (Fig. 4B). 
Methyl 2,5-dihydroxycinnamate was confirmed to in- 
hibit EGF receptor-associated tyrosine kinase in situ, as 
shown in Fig. 5. The amount of EGF receptor was not 
affected by 2,5-MeC (data not shown). 
4. DISCUSSION 
The ER12 cells showed phenotypic transformation in 
response to EGF, including morphological change, 
growth advantage, loss of stress fiber organization, and 
decrease in fibronecrin expression; and all of these phc- 
notypic changes were inhibited by erbstatin or 2,5-MeC, 
but not by its inactive analogue S-O-methylerbstatin. 
The tyrosine kinase inhibitors reversibly inhibited the 
EGF-induced DNA synthesis. Pulse addition of the in- 
hibitor indicated that tyrosine kinase activity is essential 
in Q$G, phase. 
Loss of stress fibers and a decrease in fibronectin 
expression are often observed in malignant ransforma- 
tion. Because tyrosine kinase inhibitors inhibited EGF- 
induced cytoskeletal changes and decrease in fi- 
bronectin expression, tyrosine kinase may regulate cy- 
toskeletal organization and adhesion of the cells directly 
or indirectly. Previously it was reported that EGF re- 
ceptors are associated with cytoskeletal structure [13]. 
Phosphatidylinositol turnover inhibitors such as 
inostamycin and psi-tectorigenin inhibited EGF-in- 
duced cytoskeletal change in A431 cells [14], but not 
obviously in ER12 cells. Therefore, it might be less 
likely that tyrosine kinase regulates the cytoskeleton 
through phosphatidylinositol turnover. 
EGF receptors on the tumour cell surface would con- 
tribute to the development of neoplasms in vivo in re- 
sponse to EGF and related growth factors. It may be 
possible to inhibit such development by use of tyrosine 
kinase inhibitors of low molecular weight. 
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